Scroll to top

Scroll to top

News Releases

Home
Investors
News Releases

News Releases

Month Year

Month Year

Investor Alerts

August 10, 2020

Immunic, Inc. Announces Closing of $103.5 Million Public Offering, including Full Exercise of Underwriters' Option to Purchase Additional Shares
August 4, 2020

Immunic, Inc. Announces Pricing of $90.0 Million Public Offering of Common Stock
August 3, 2020

Immunic, Inc. Announces Proposed Public Offering of 5 Million Shares of Common Stock
August 2, 2020

Immunic, Inc. Reports Positive Top-line Data from Phase 2 EMPhASIS Trial of IMU-838 in Patients with Relapsing-Remitting Multiple Sclerosis

- Study Meets Primary and Key Secondary Endpoints with High Statistical Significance Indicating Activity for IMU-838 in Relapsing-Remitting Multiple Sclerosis -
July 30, 2020

Immunic, Inc. to Report Second Quarter 2020 Financial Results and Provide Corporate Update
July 29, 2020

Immunic, Inc. to Participate in Investor Conferences in August
July 27, 2020

Immunic, Inc. Announces First Patients Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of IMU-838 in Combination with Oseltamivir for the Treatment of Patients with Moderate-to-Severe COVID-19

- Study Being Conducted in Collaboration with University Hospitals Coventry and Warwickshire NHS Trust -
June 22, 2020

Immunic, Inc. to Join Russell 3000® Index
June 15, 2020

Immunic, Inc. Announces First Patients Dosed in its Phase 2, CALVID-1 Clinical Trial of IMU-838 in COVID-19
June 10, 2020

Immunic, Inc. Announces Pricing of $25 Million Public Offering of Common Stock
June 9, 2020

Immunic, Inc. Announces Proposed Public Offering of Common Stock
June 9, 2020

Immunic, Inc. Announces U.S. Food and Drug Administration Allowance of its Phase 2, CALVID-1 Clinical Trial of IMU-838 in COVID-19
May 29, 2020

Immunic, Inc. to Participate in Investor and Industry Conferences in June
May 19, 2020

Immunic, Inc. to Host Virtual R&D Day Today, May 19, 2020

- Presentation Will Include Preclinical Data of IMU-838 Against SARS-CoV-2 as Well as First Pharmacokinetic Data From the Ongoing Phase 1 Clinical Trial of IMU-935 -
May 13, 2020

Immunic, Inc. Receives First Regulatory Approval from German Health Authority BfArM to Initiate a Phase 2 Clinical Trial of its Selective Oral DHODH Inhibitor, IMU-838, in COVID-19 Patients
May 8, 2020

Immunic, Inc. Reports First Quarter 2020 Financial Results and Highlights Recent Activity
April 23, 2020

Immunic, Inc. Announces Pricing of $15 Million Financing
April 21, 2020

Immunic, Inc. Reports that IMU-838, a Selective Oral DHODH Inhibitor, Has Demonstrated Preclinical Activity Against SARS-CoV-2 and Explores Plans for a Phase 2 Clinical Trial in COVID-19 Patients

- In Cellular Assays with SARS-CoV-2 Clinical Isolates, IMU-838 Shows Ability to Inhibit Viral Replication of SARS-CoV-2 -
April 17, 2020

Immunic, Inc. Announces Changes to Executive Team
March 16, 2020

Immunic, Inc. Reports Year End 2019 Financial Results and Highlights Recent Achievements

- Top-Line Data from Phase 2 EMPhASIS Trial in Relapsing-Remitting Multiple Sclerosis Expected in Third Quarter 2020 -
February 11, 2020

Immunic, Inc. to Participate in Scientific and Investor Conferences in February
January 8, 2020

Immunic Exercises its Option for the Exclusive Worldwide License to IMU-856 from Daiichi Sankyo Co., Ltd.

Phase 1 Clinical Studies to begin in First Half of 2020
December 4, 2019

Immunic, Inc. to Present Data on IMU-856, for the First Time, at the Crohn's and Colitis Foundation's IBD Innovate Conference

IMU-856 has the potential to address one of the putative root causes of inflammatory bowel disease without impairing the immune system
November 25, 2019

Immunic, Inc. to Participate in Investor and Scientific Conferences in December
November 19, 2019

Immunic, Inc. Expands Board of Directors with Appointment of Biotechnology Executive Barclay A. Phillips

Show per page